

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

AMPHOTERICIN B LIPOSOME FOR INJECTION OBTAINS DRUG REGISTRATION APPROVAL

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Amphotericin B Liposome for Injection (the “**Product**”) developed by the Group has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China.

The indications for this approval include: 1) treatment of systemic fungal infections caused by susceptible fungi; 2) treatment of patients with neutropenia and unexplained fever who are highly suggestive of the presence of systemic fungal infections; and 3) treatment of visceral leishmaniasis in adults and children.

Amphotericin B is a type of polyene antibiotics and is one of the most potent and broad spectrum drugs for the prevention and treatment of invasive fungal diseases. It kills fungal cells by binding to ergosterol, a sterol component in the cell membrane of susceptible fungi, to form transmembrane channels which lead to alterations in cell membrane permeability.

The Product utilises a liposomal drug delivery system, encapsulating amphotericin B into small unilamellar liposomes of less than 100nm formed by hydrogenated soybean phosphatidylcholine, distearoyl phosphatidylglycerol and cholesterol. Compared with other amphotericin B injections on the market, the Product mainly exists in the bloodstream in liposomal form, which can significantly reduce the binding of free amphotericin B to renal tubular epithelial cells, resulting in significant reduction of drug nephrotoxicity, decrease in infusion reactions, shortened administration duration, increase in dosage and improvement of therapeutic index.

The approval of the Product marks significant progress of the Group in the fields of nanomedicine research and development and antifungal infections, and further enriches the Group's product portfolio in antifungal infections.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 16 September 2024

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. JIANG Hao, Dr. YAO Bing and Mr. CAI Xin as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.